trans-(3'S,4S)-4-tert-Butoxycarbonylamino-5-(2'-oxopyrrolidin-3'-yl)pent-2-enoic Acid Cyclopentyl Ester | 343566-66-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: trans-(3'S,4S)-4-tert-Butoxycarbonylamino-5-(2'-oxopyrrolidin-3'-yl)pent-2-enoic Acid Cyclopentyl Ester
• 英文别名: cyclopentyl (E,4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
• CAS: 343566-66-5
• 化学式: C₁₉H₃₀N₂O₅
• 分子量: 366.458
• InChiKey: JMQHFEWQJCOTKR-NYCDYWJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  93.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  trans-(3'S,4S)-4-tert-Butoxycarbonylamino-5-(2'-oxopyrrolidin-3'-yl)pent-2-enoic Acid Cyclopentyl Ester 在 三氟乙酸 作用下， 以 四氯化碳 、 二氯甲烷 为溶剂， 生成 trans-(3'S,4S)-4-Amino-5-(2'-oxo-pyrrolidin-3'-yl)pent-2-enoic acid Cyclopentyl Ester
  参考文献：
  名称：

  Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis

  摘要：

  披露了具有以下公式的化合物： 1 其中公式变量如本文所述定义，这些化合物能够有优势地抑制或阻断小RNA病毒3C蛋白酶的生物学活性。还披露了具有以下公式的化合物： 2 其中公式变量如本文所述定义，这些化合物能够有优势地抑制或阻断小RNA病毒3C蛋白酶的生物学活性。这些化合物以及含有这些化合物的药物组合物对于治疗感染了一种或多种小RNA病毒的患者或宿主是有用的，例如鼻病毒3C蛋白酶。还描述了用于制备这些化合物的中间体和合成方法。

  公开号：

  US20010047006A1
• 作为产物：
  描述：

  tert-butyl N-[(2S)-1-[(3S)-1-[(2,4-dimethoxyphenyl)methyl]-2-oxopyrrolidin-3-yl]-3-oxopropan-2-yl]carbamate 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 生成 trans-(3'S,4S)-4-tert-Butoxycarbonylamino-5-(2'-oxopyrrolidin-3'-yl)pent-2-enoic Acid Cyclopentyl Ester
  参考文献：
  名称：

  Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics

  摘要：

  The optimization of the pharmacokinetic performance of various 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors following oral administration to either beagle dogs or CM-monkeys is described. The molecules described in this work are composed of a 2-pyridone-containing peptidomimetic binding determinant and an alpha,beta-unsaturated ester Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. Modification of the ester contained within these compounds is detailed along with alteration of the P-2 substituent present in the peptidomimetic portion of the inhibitors. The pharmacokinetics of several inhibitors in both dogs and monkeys are described (7 h plasma concentrations after oral administration) along with their human plasma stabilities, stabilities in incubations with human, dog, and monkey microsomes and hepatocytes, Caco-2 permeabilities, and aqueous solubilities. Compounds containing an alpha,beta-unsaturated ethyl ester fragment and either an ethyl or propargyl. P-2 moiety displayed the most promising combination of 3C enzyme inhibition (k(obs)/[1] 170 000-223 000 M-1 s(-1)), antiviral activity (EC50 = 0.047-0.058 muM, mean vs seven HRV serotypes), and pharmacokinetics following oral administration (7 h dog plasma levels = 0.248-0.682 muM; 7 h CM-monkey plasma levels = 0.057-0.896 muM).

  DOI：

  10.1021/jm030166l

文献信息

• US6514997B2
  申请人：——

  公开号：US6514997B2

  公开（公告）日：2003-02-04
• Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
  申请人：——

  公开号：US20010047006A1

  公开（公告）日：2001-11-29

  Compounds of the formula: 1 where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the picornaviral 3C protease. Also disclosed are compounds of the formula: 2 where the formula variables are as defined herein that advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as rhinovirus 3C proteases. Intermediates and synthetic methods for preparing such compounds are also described.

  披露了具有以下公式的化合物： 1 其中公式变量如本文所述定义，这些化合物能够有优势地抑制或阻断小RNA病毒3C蛋白酶的生物学活性。还披露了具有以下公式的化合物： 2 其中公式变量如本文所述定义，这些化合物能够有优势地抑制或阻断小RNA病毒3C蛋白酶的生物学活性。这些化合物以及含有这些化合物的药物组合物对于治疗感染了一种或多种小RNA病毒的患者或宿主是有用的，例如鼻病毒3C蛋白酶。还描述了用于制备这些化合物的中间体和合成方法。
• Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics
  作者：Peter S. Dragovich、Thomas J. Prins、Ru Zhou、Theodore O. Johnson、Ye Hua、Hiep T. Luu、Sylvie K. Sakata、Edward L. Brown、Fausto C. Maldonado、Tove Tuntland、Caroline A. Lee、Shella A. Fuhrman、Leora S. Zalman、Amy K. Patick、David A. Matthews、Ellen Y. Wu、Ming Guo、Bennett C. Borer、Naresh K. Nayyar、Terence Moran、Lijian Chen、Paul A. Rejto、Peter W. Rose、Mark C. Guzman、Elena Z. Dovalsantos、Steven Lee、Kevin McGee、Michael Mohajeri、Andreas Liese、Junhua Tao、Maha B. Kosa、Bo Liu、Minerva R. Batugo、Jean-Paul R. Gleeson、Zhen Ping Wu、Jia Liu、James W. Meador、Rose Ann Ferre

  DOI：10.1021/jm030166l

  日期：2003.10.1

  The optimization of the pharmacokinetic performance of various 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors following oral administration to either beagle dogs or CM-monkeys is described. The molecules described in this work are composed of a 2-pyridone-containing peptidomimetic binding determinant and an alpha,beta-unsaturated ester Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. Modification of the ester contained within these compounds is detailed along with alteration of the P-2 substituent present in the peptidomimetic portion of the inhibitors. The pharmacokinetics of several inhibitors in both dogs and monkeys are described (7 h plasma concentrations after oral administration) along with their human plasma stabilities, stabilities in incubations with human, dog, and monkey microsomes and hepatocytes, Caco-2 permeabilities, and aqueous solubilities. Compounds containing an alpha,beta-unsaturated ethyl ester fragment and either an ethyl or propargyl. P-2 moiety displayed the most promising combination of 3C enzyme inhibition (k(obs)/[1] 170 000-223 000 M-1 s(-1)), antiviral activity (EC50 = 0.047-0.058 muM, mean vs seven HRV serotypes), and pharmacokinetics following oral administration (7 h dog plasma levels = 0.248-0.682 muM; 7 h CM-monkey plasma levels = 0.057-0.896 muM).